7-{2S-[3R-hydroxy-4-(3-trifluoromethoxyphenyl)-butyl]-5-oxopyrrolidin-1-yl}-heptanoic acid | 346673-09-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 7-{2S-[3R-hydroxy-4-(3-trifluoromethoxyphenyl)-butyl]-5-oxopyrrolidin-1-yl}-heptanoic acid
• 英文别名: 7-{2S-[3R-hydroxy-4-(3-trifluoromethoxyphenyl)butyl]-5-oxopyrrolidine-1-yl}heptanoic acid；7-((S)-2-((R)-3-hydroxy-4-(3-(trifluoromethoxy)phenyl)butyl)-5-oxopyrrolidin-1-yl)heptanoic acid；7-[(2S)-2-[(3R)-3-hydroxy-4-[3-(trifluoromethoxy)phenyl]butyl]-5-oxopyrrolidin-1-yl]heptanoic acid
• CAS: 346673-09-4
• 化学式: C₂₂H₃₀F₃NO₅
• 分子量: 445.479
• InChiKey: SWEULPXWCJTJIE-ZWKOTPCHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  31
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  87.1
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  7-溴庚酸甲酯 在 palladium on activated charcoal 盐酸 、 sodium hydroxide 、 氢气 、 sodium hexamethyldisilazane 、 三氟乙酸吡啶 、 二甲基亚砜 、 (R)-2-甲基-CBS-恶唑硼烷 、 儿萘酚硼烷 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 生成 7-{2S-[3R-hydroxy-4-(3-trifluoromethoxyphenyl)-butyl]-5-oxopyrrolidin-1-yl}-heptanoic acid
  参考文献：
  名称：

  Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats

  摘要：

  Heptanoic acid lactams. exemplified by 2, were identified as highly selective EP4 agonists via high throughput screening. Lead optimization led to the identification of lactams with a 30-fold increase in EP4 potency in vitro. Compounds demonstrated robust bone anabolic effects when administered in vivo in rat models of osteoporosis. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.018

文献信息

• EP4 receptor selective agonists in the treatment of osteoporosis
  申请人：——

  公开号：US20010047105A1

  公开（公告）日：2001-11-29

  This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists. This invention is especially directed to those methods wherein the EP4 receptor selective agonist is a compound of Formula I: 1 wherein the variables are as defined in the specification.

  这项发明涉及治疗低骨密度等病症的方法，特别是骨质疏松症、脆弱、骨折、骨缺陷、儿童特发性骨质流失、牙槽骨流失、下颌骨流失、骨折、骨切术、与牙周炎相关的骨流失或假体生长的方法，包括给予EP4受体选择性前列腺素激动剂。这项发明特别涉及EP4受体选择性激动剂为Formula I中的化合物的方法：1其中变量如规范中所定义。
• Methods of treatment with selective EP4 receptor agonists
  申请人：——

  公开号：US20030207925A1

  公开（公告）日：2003-11-06

  The present invention provides a method of treating hypertension, liver failure, loss of patency of ductus arteriosus, glaucoma or ocular hypertension in a patient, comprising administering to the patient a therapeutically effective amount of a selective EP 4 receptor agonist of Formula I 1 or a prodrug thereof, a pharmaceutically acceptable salt of the selective EP 4 receptor agonist or prodrug or a stereoisomer or diastereomeric mixture of the EP 4 receptor agonist, prodrug or salt, wherein the variables X, Z, Q, , and R 2 are as defined in the specification.

  本发明提供了一种治疗患有高血压、肝功能衰竭、动脉导管未开放、青光眼或眼压增高的患者的方法，包括向患者施用公式I1中的选择性EP4受体激动剂或其前药的治疗有效量、选择性EP4受体激动剂的药学上可接受的盐或前药的盐，或EP4受体激动剂、前药或盐的立体异构体或对映体混合物，其中变量X、Z、Q、和R2如规范所定义。
• EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS
  申请人：Pfizer Products Inc.

  公开号：EP1339678A2

  公开（公告）日：2003-09-03
• USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES
  申请人：Pfizer Products Inc.

  公开号：EP1487437B1

  公开（公告）日：2006-08-16
• METHODS OF TREATMENT WITH SELECTIVE EP4 RECEPTOR AGONISTS
  申请人：Pfizer Products Inc.

  公开号：EP1487437A1

  公开（公告）日：2004-12-22